CNTF Phase 3 Trial Enrollment Complete

September 21, 2020

Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is conducting a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a multi-center trial, with clinical sites in the United States, Europe, and Australia.

The clinical trial tests whether CNTF, a small molecule, is an effective treatment in patients with macular telangiectasia type 2.  The purpose of the trial is to investigate whether CNTF can slow the progression of MacTel when compared to a sham procedure.

Participants in the Phase 3 trial will be followed for two years, with a total of nine visits. The study will be completed by the end of 2022.

The Phase 1 and Phase 2 participants continue to be followed in a long-term extension study, as well as Phase 3 patients who have completed the trial.


Image credit: